Abstract:

Lung cancer is the most common type of cancer with more than two million new cases worldwide, according to 2018 data, and accounts for 18.4% of cancer-related deaths. Oxidative stress can play a role in all stages of carcinogenesis. In this study, the aim is to evaluate the thyol-disulfite balance that can be an indicator of immediate antioxidant capacity diagnosed in HIV patients and compare it with healthy controls. Method and Requirements: The new diagnosis advanced phase of KHDAK with 43 patients and group of patients included in the 50 healthy control studies compatible with age and gender. Blood samples required for the thyol-disulphite homeostasis analysis of patients were obtained immediately. Serum thyol and dysulphite samples of the patient and control group were measured by the automatic spectrophotometric method. The clinical, radiological and laboratory characteristics of the patients were recorded. Results: Natural thyol and total thyol values have been shown to be significantly lower in the patient group compared to the control group (p<0,001). There was no significant difference between the groups in terms of disulfite/natural thyol ratio from disulfite levels and antioxidant capacity indicators. The average overall survival was identified as 9.1 months (1,2 - 37.9 months). The effects of thyol and disulfite values on resilience have not been identified. The low levels of tiol compounds in the patient group from non-enzimatic antioxidant compounds may be due to the increased use shown to eliminate increased production of ROS in the KHDAK pathogenesis. Antioxidant thyol compounds that are reduced in the process can also be the cause and the result of increased ROS. No increase in disulfite values can be associated with an increased cell cycle.

Keywords: